When you look at a comparison between PRICERA™ and NR (Nicotinamide Riboside) and NMN (Nicotinamide Mononucleotide) –

Pricera comes out the clear winner!

PRICERA™ clinically proven to outperform both NR* and NMN**
Increases NAD+
Simultaneously increases ATP, NAD+, and GSH
Utilizes the dominant pathway for NAD+ synthesis
Utilizes shunt pathway for NAD+ synthesis
Stable in most applications
Orally bioavailable (high amounts end up in blood)
Survives digestive process intact
*NR – Nicotinamide Riboside   **NMN – Nicotinamide Mononucleotide

Supporting Documentation:

  • Avery B (Department of Pharmaceutics and Drug Delivery, The University of Mississippi), 2017. Pharmacokinetic Analysis of Plasma Nicotinamide and 1-Methyl Nicotinamide Concentrations in Toxicokinetic Study of NIAGEN (Nicotinamide Riboside).Study Report No AV151003. Unpublished Study Report, 9 pp.
  • Liu L. et al. Quantitative analysis of NAD synthesis-breakdown fluxes. CellMetab.27, 1067–1080 (2018).
  • Xue, YQ, Increasing NAD level by D-ribose and its combinations. PCT/US2019/031889 patent pending.
  • https://www.jstage.jst.go.jp/article/endocrj/advpub/0/advpub_EJ19-0313/_article
  • https://www.nature.com/articles/s41467-018-03421-7